Human medicines European public assessment report (EPAR): mCOMBRIAX, Influenza,COVID-19 mRNA vaccine, Status: Opinion

Human medicines European public assessment report (EPAR): Ojemda, tovorafenib, Status: Opinion

Human medicines European public assessment report (EPAR): Onerji, levodopa,carbidopa, Status: Opinion

Human medicines European public assessment report (EPAR): Palsonify, paltusotine, Status: Opinion

Human medicines European public assessment report (EPAR): Poherdy, pertuzumab, Status: Opinion

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Status: Opinion

Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Status: Opinion

Human medicines European public assessment report (EPAR): Zandoriah, teriparatide, Status: Opinion

Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2026